Published in Int J Oncol on May 01, 2006
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. J Med Chem (2010) 2.12
Cimetidine and Clobenpropit Attenuate Inflammation-Associated Colorectal Carcinogenesis in Male ICR Mice. Cancers (Basel) (2016) 1.40
The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia (2008) 1.13
Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier. Drug Metab Dispos (2009) 0.93
Cimetidine inhibits salivary gland tumor cell adhesion to neural cells and induces apoptosis by blocking NCAM expression. BMC Cancer (2008) 0.84
Histamine and histamine receptor regulation of gastrointestinal cancers. Transl Gastrointest Cancer (2012) 0.80
Histamine regulation of hyperplastic and neoplastic cell growth in cholangiocytes. World J Gastrointest Pathophysiol (2010) 0.78
Crystal structure transformations and dissolution studies of cimetidine-piroxicam coprecipitates and physical mixtures. AAPS PharmSciTech (2009) 0.77
Glioblastoma cells express functional cell membrane receptors activated by daily used medical drugs. J Cancer Res Clin Oncol (2009) 0.77
A phase ΙI clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci (2016) 0.76
Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer. Cancer Sci (2016) 0.76
Repurposing cimetidine for cholangiocarcinoma: Antitumor effects in vitro and in vivo. Oncol Lett (2017) 0.75
Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma. Oncotarget (2017) 0.75
Characterization of cimetidine-piroxicam coprecipitate interaction using experimental studies and molecular dynamic simulations. AAPS PharmSciTech (2010) 0.75
Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol (2005) 3.46
Galectin-1: a small protein with major functions. Glycobiology (2006) 3.06
Efficacy and complications of covered Wallstents in malignant distal biliary obstruction. Gastrointest Endosc (2005) 2.18
Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy. Clin Gastroenterol Hepatol (2008) 2.03
Temporary placement of covered self-expandable metal stents in benign biliary strictures: a new paradigm? (with video). Gastrointest Endosc (2008) 2.02
EUS-guided pancreaticogastrostomy: analysis of its efficacy to drain inaccessible pancreatic ducts. Gastrointest Endosc (2006) 1.98
Interventional EUS-guided cholangiography: evaluation of a technique in evolution. Gastrointest Endosc (2006) 1.94
Removal of self-expandable metallic Wallstents. Gastrointest Endosc (2004) 1.88
Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist (2007) 1.85
Safety and efficacy of ERCP in pregnancy. Gastrointest Endosc (2004) 1.79
Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys (2004) 1.78
Temporary placement of covered self-expandable metallic stents in patients with biliary leak: midterm evaluation of a pilot study. Gastrointest Endosc (2007) 1.71
Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta (2007) 1.70
3-Aryl-2-quinolone derivatives: synthesis and characterization of in vitro and in vivo antitumor effects with emphasis on a new therapeutical target connected with cell migration. J Med Chem (2002) 1.59
Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev (2007) 1.50
Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res (2010) 1.50
Cell culture processes for monoclonal antibody production. MAbs (2010) 1.48
Prospective evaluation of pancreatic sphincterotomy as a precut technique for biliary cannulation. Clin Gastroenterol Hepatol (2004) 1.45
Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release. J Cell Mol Med (2012) 1.40
A retrospective review of the course of patients with pancreatitis discharged on jejunal feedings. Nutr Clin Pract (2002) 1.38
Galectins and cancer. Biochim Biophys Acta (2002) 1.37
Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med (2004) 1.35
Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia (2008) 1.34
Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res (2009) 1.34
Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis (2004) 1.31
Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol Appl Pharmacol (2005) 1.28
Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem (2009) 1.25
The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia (2007) 1.22
Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery (2008) 1.21
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med (2009) 1.21
Brain stem metastases treated with radiosurgery: prognostic factors of survival and life expectancy estimation. Surg Neurol (2008) 1.20
Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther (2006) 1.17
EUS-guided transhepatic cholangiography: report of 6 cases. Gastrointest Endosc (2005) 1.15
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia (2010) 1.15
Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer (2003) 1.15
Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol (2002) 1.14
Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia (2006) 1.14
Preliminary experience with the enterprise stent for endovascular treatment of complex intracranial aneurysms: potential advantages and limiting characteristics. Neurosurgery (2008) 1.14
Interventional EUS cholangiography: A report of five cases. Gastrointest Endosc (2004) 1.13
The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia (2008) 1.13
Digital holographic microscopy for the three-dimensional dynamic analysis of in vitro cancer cell migration. J Biomed Opt (2006) 1.12
The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol (2007) 1.11
Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J (2010) 1.10
Autophagy, the Trojan horse to combat glioblastomas. Neurosurg Focus (2006) 1.08
Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. J Med Chem (2009) 1.08
Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia (2009) 1.07
EMR of ampullary gangliocytic paragangliomas. Gastrointest Endosc (2005) 1.07
Na+/K+-ATPase alpha subunits as new targets in anticancer therapy. Expert Opin Ther Targets (2008) 1.07
Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol (2008) 1.06
The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther (2006) 1.05
Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol (2008) 1.05
Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol (2003) 1.05
Videomicroscopic extraction of specific information on cell proliferation and migration in vitro. Exp Cell Res (2008) 1.05
Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer (2003) 1.04
Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1. Immunol Lett (2009) 1.04
Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol (2007) 1.04
Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. Neurosurgery (2009) 1.03
Multimodality Treatment With Helical Tomotherapy Intensity Modulated Radiotherapy, Capecitabine, and Photodynamic Therapy is Feasible and Well Tolerated in Patients With Hilar Cholangiocarcinoma. Gastrointest Cancer Res (2008) 1.03
Amaryllidaceae alkaloids belonging to different structural subgroups display activity against apoptosis-resistant cancer cells. J Nat Prod (2010) 1.02
Galectins and gliomas. Brain Pathol (2009) 1.01
Metabolic flux analysis and pharmaceutical production. Metab Eng (2009) 1.01
Evaluation of the antiproliferative activity of diterpene isonitriles from the sponge Pseudoaxinella flava in apoptosis-sensitive and apoptosis-resistant cancer cell lines. J Nat Prod (2011) 1.01
Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun (2005) 1.00
UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia (2008) 0.99
Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg (2006) 0.99
Therapeutic agents triggering nonapoptotic cancer cell death. J Med Chem (2013) 0.98
111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur J Nucl Med Mol Imaging (2003) 0.98
Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem (2006) 0.98
Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol (2010) 0.98
Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis (2005) 0.98
Meshed capillary vessels found on narrow-band imaging without optical magnification effectively identifies colorectal neoplasia: a North American validation of the Japanese experience. Gastrointest Endosc (2010) 0.98
Up-regulation of galectin-3 and its ligands by Trypanosoma cruzi infection with modulation of adhesion and migration of murine dendritic cells. Glycobiology (2004) 0.98
Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol (2006) 0.97
EUS antegrade pancreatography with gastropancreatic duct stent placement: Review of two cases. Gastrointest Endosc (2003) 0.97
Hemicerebellectomy blocks the enhancement of cortical motor output associated with repetitive somatosensory stimulation in the rat. J Physiol (2005) 0.97
Galectin-1 is overexpressed in nasal polyps under budesonide and inhibits eosinophil migration. Lab Invest (2002) 0.97
A model-based approach for automated in vitro cell tracking and chemotaxis analyses. Cytometry A (2004) 0.96
In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol (2002) 0.96
Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol (2012) 0.96
Fungal metabolites with anticancer activity. Nat Prod Rep (2014) 0.96
In search of a cytostatic agent derived from the alkaloid lycorine: synthesis and growth inhibitory properties of lycorine derivatives. Bioorg Med Chem (2011) 0.95
Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents. J Med Chem (2011) 0.95
Galectin-1 is implicated in the protein kinase C epsilon/vimentin-controlled trafficking of integrin-beta1 in glioblastoma cells. Brain Pathol (2009) 0.95
Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod Pathol (2002) 0.95
Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med (2004) 0.95
Synovial cysts of the lumbar spine: surgery-related results and outcome. J Neurosurg (2003) 0.95
EUS-guided drainage of bilomas: a new alternative? Gastrointest Endosc (2008) 0.95
In vitro pharmacological and toxicological effects of norterpene peroxides isolated from the Red Sea sponge Diacarnus erythraeanus on normal and cancer cells. J Nat Prod (2013) 0.94
Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. Oncotarget (2012) 0.94
Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the organization of their actin cytoskeleton. Biochim Biophys Acta (2002) 0.94
Exploring natural product chemistry and biology with multicomponent reactions. 5. Discovery of a novel tubulin-targeting scaffold derived from the rigidin family of marine alkaloids. J Med Chem (2013) 0.94
Persistent hydrocephalus after early surgical management of posterior fossa tumors in children: is routine preoperative endoscopic third ventriculostomy justified? J Neurosurg (2005) 0.93